Subsense Inc. is at the forefront of developing innovative brain-computer interface (BCI) technologies, particularly focusing on non-invasive solutions that leverage biocompatible nanoparticles. These nanoparticles are engineered to safely integrate with the human brain, enabling the stimulation and recording of neural activity without the need for surgical implants. This non-invasive approach not only enhances user safety and comfort but also broadens accessibility for individuals with neurological disorders and paralysis. The technology aims to transform thoughts into digital commands, facilitating improved independence and interaction with digital devices, while also offering new avenues for treating neurodegenerative diseases through targeted brain stimulation.

The company's vision extends beyond individual applications, aspiring to create a seamless synergy between human cognition and technology. Subsense's BCI technology is designed to enable real-time monitoring of brain activity, which could lead to more accurate diagnoses and better-informed treatment plans for various neurological conditions. By focusing on the integration of advanced nanotechnology with neurotechnology, Subsense aims to revolutionize human-machine interaction, making it more intuitive and accessible. Their commitment to research and development is supported by a team of experts across multiple disciplines, ensuring that their innovations not only meet current medical needs but also pave the way for future advancements in healthcare technology.

United States

Subsense is a neurotechnology company developing the first non-surgical, nanoparticle-based bidirectional brain-computer interface. Subsense is partnered with leading global neurological research institutions. The company is venture-backed with its global headquarters in Palo Alto, California.

Subsense Inc.

Company Details